Bellvitge Biomedical Research Institute IDIBELL
Barcelona, Spain
Description
A Postdoctoral Contract for a Bionformatician is offered in the Chromatin and Disease Group (led by Dr. Esteban Ballestar) within the Cancer Epigenetics and Biology Programme (PEBC) at the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona. Research in the laboratory focuses in epigenetic deregulation mechanisms in the immune system, particularly in the context of autoimmune disease and different differentiation models relevant to immune-related disease [Javierre et al. (2010) Genome Res. 20, 170-179; Ballestar (2011) Nature Reviews Rheumatology 7, 263-271; Rodriguez-Ubreva et al. (2012) Nucleic Acids Research 40, 1954-1968; Hernando et al. (2013) Genome Biol 14, R3; de la Rica et al. (2013) Genome Biol 14, R99, Rodriguez-Ubreva et al. Mol Cell Biol (2014)].
The Chromatin and Disease Group (PEBC, IDIBELL) offers this position in the context of an EU grant for the integrated analisys of DNA methylation, expression, miRNA OMICS data. The project joins efforts from international and multidisciplinary fundamental and clinical labs. We are seeking for an enthusiastic, hardworker bioinformatician with strong background in epigenomics and bioinformatic analysis of high-throughput omics data.
• PhD degree in Bioinformatics, Biology, Molecular Biology, Genetics or related.
• Strong background in bioinformatic analysis of high-throughput DNA methylation, ChIP-on-chip, ChIP-seq, RNA-seq data.
• Advanced English Level.
More information and applications
• Full time contract for immediate incorporation.
• Starting date: Feb-March 2014.
• Applications must include curriculum vitae with a cover letter and contacts for 2 references.
Dr. Esteban Ballestar
Chromatin and Disease Group
Cancer Epigenetics and Biology Programme (PEBC)
Bellvitge Biomedical Research Institute (IDIBELL)
Avda. Gran Via 199-203
08908 L´Hospitalet de Llobregat, Barcelona, Spain
eballestar@idibell.org
http://www.idibell.cat/modul/Chromatin-and-Disease/en
No comments:
Post a Comment